Shopping Cart
- Remove All
Your shopping cart is currently empty
Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $645 | In Stock | |
| 5 mg | $1,690 | In Stock | |
| 10 mg | $2,680 | 2-4 weeks | |
| 25 mg | $3,990 | 2-4 weeks |
| Description | Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO. |
| In vivo | Faricimab (10 mg/kg, intraperitoneal injection, once a week, 1-5 weeks) can reduce spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1+, CD11b+, CD45+ cell infiltration in JR5558 mice. [1] |
| Synonyms | RG-7716, RG7716 |
| Cas No. | 1607793-29-2 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.